AU2393992A - Combination therapy using bioflavonoid compounds with anti-cancer drugs - Google Patents

Combination therapy using bioflavonoid compounds with anti-cancer drugs

Info

Publication number
AU2393992A
AU2393992A AU23939/92A AU2393992A AU2393992A AU 2393992 A AU2393992 A AU 2393992A AU 23939/92 A AU23939/92 A AU 23939/92A AU 2393992 A AU2393992 A AU 2393992A AU 2393992 A AU2393992 A AU 2393992A
Authority
AU
Australia
Prior art keywords
combination therapy
cancer drugs
bioflavonoid compounds
bioflavonoid
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23939/92A
Other languages
English (en)
Inventor
Barry M. Markaverich
Rajender Singh Varma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2393992A publication Critical patent/AU2393992A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU23939/92A 1991-07-24 1992-07-17 Combination therapy using bioflavonoid compounds with anti-cancer drugs Abandoned AU2393992A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73804491A 1991-07-24 1991-07-24
US738044 1996-10-25

Publications (1)

Publication Number Publication Date
AU2393992A true AU2393992A (en) 1993-02-23

Family

ID=24966338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23939/92A Abandoned AU2393992A (en) 1991-07-24 1992-07-17 Combination therapy using bioflavonoid compounds with anti-cancer drugs

Country Status (2)

Country Link
AU (1) AU2393992A (fr)
WO (1) WO1993001824A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271301B (it) * 1994-12-20 1997-05-27 Indena Spa Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono
WO2005016864A1 (fr) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Agents anticancereux a base de nitro-alcene conjugue utilisant le metabolisme des isoprenoides
WO2005077405A1 (fr) * 2004-02-06 2005-08-25 Cancer Treatment International Compositions et methodes de traitement du cancer par elevation systemique de lactate et depletion d'arginine
WO2010023195A2 (fr) 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions et procédés pour le traitement du cancer
TW201036624A (en) * 2009-03-27 2010-10-16 Biotropics Malaysia Berhad Aurones as selective PDE inhibitors and their use in neurological conditions and disorders
TW201036608A (en) * 2009-03-27 2010-10-16 Biotropics Malaysia Berhad Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases
US9884825B2 (en) 2012-08-03 2018-02-06 Georgia State University Research Foundation, Inc. Curcumin analogs and methods of making and using thereof
WO2017180644A1 (fr) 2016-04-11 2017-10-19 Middle Tennessee State University Aurones thérapeutiques
KR102609490B1 (ko) * 2020-09-01 2023-12-04 부산대학교 산학협력단 Pak1 억제활성을 갖는 신규 화합물 및 이의 용도

Also Published As

Publication number Publication date
WO1993001824A1 (fr) 1993-02-04

Similar Documents

Publication Publication Date Title
AU4227793A (en) Drug infuser
AU2263692A (en) Multiple pharmaceutical syringe
AU3891889A (en) Cardioplegia administration set
AU2080992A (en) Iv administration set infiltration monitor
GB9016789D0 (en) Medicament administering devices
AU2087992A (en) Pharmaceutical combination formulation
AU3888793A (en) Novel medicament
AU7320394A (en) Pro-cytotoxic drug conjugates for anticancer therapy
IL103303A0 (en) Medicament
GB9200417D0 (en) Cytotoxic drug therapy
AU1330392A (en) Safety syringe
AU2782592A (en) Thermal enhancement of transdermal drug administration
AU4377793A (en) Alternative receptor therapy
AU2657192A (en) Simplified security syringe
AU2393992A (en) Combination therapy using bioflavonoid compounds with anti-cancer drugs
GB9121463D0 (en) Medicament
AU663106B2 (en) Porphyrin-based anti-HIV drug
AU662160B2 (en) Analgesic
AU8614291A (en) Device for administering drugs
AU2493792A (en) Pharmaceutical preparation
AU1740692A (en) New medicinal use
AU1065088A (en) Pharmaceutical unit
AU1103092A (en) Immunopotentiating drug
AU2381392A (en) Device for administering bimakalim transdermally
AU1676192A (en) Multisubstituted 1-hydroxy-9-acridones with anticancer activity